ahlam1399
03-18-2016, 10:13 AM
BRIEF-Galapagos presents filgotinib results at ECCO
* Results from 10-week analysis of phase 2 study with filgotinib in Crohn's disease presented at ECCO Source text for Eikon: Further company coverage: (Gdynia Newsroom)
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e58c67c/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=70DIcf7dFVI:4P8OG-lLtgQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=70DIcf7dFVI:4P8OG-lLtgQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=70DIcf7dFVI:4P8OG-lLtgQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=70DIcf7dFVI:4P8OG-lLtgQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=70DIcf7dFVI:4P8OG-lLtgQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/70DIcf7dFVI
* Results from 10-week analysis of phase 2 study with filgotinib in Crohn's disease presented at ECCO Source text for Eikon: Further company coverage: (Gdynia Newsroom)
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e58c67c/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=70DIcf7dFVI:4P8OG-lLtgQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=70DIcf7dFVI:4P8OG-lLtgQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=70DIcf7dFVI:4P8OG-lLtgQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=70DIcf7dFVI:4P8OG-lLtgQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=70DIcf7dFVI:4P8OG-lLtgQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/70DIcf7dFVI